Unreported / Non-Citable
Background
In November 2021, the Drug Enforcement Agency executed search warrants at Raytwain Crookshank’s primary residence and a secondary “stash” house following surveillance initiated by an anonymous tip. Investigators discovered four kilograms of heroin, over ten kilograms of methamphetamine, and multiple firearms. Crookshank was subsequently charged with felon in possession of a firearm, possession with intent to distribute methamphetamine, and possession with intent to distribute fentanyl.
On November 21, 2022, Crookshank pleaded guilty to the methamphetamine count. In March 2023, the court sentenced him to 240 months’ imprisonment. Following a retroactive guideline amendment, the sentence was reduced to 213 months in January 2024. Notably, Crookshank was on parole for a prior twenty-year prison sentence for felon in possession of a weapon at the time of the current offenses.
In November 2025, Crookshank filed a motion for compassionate release under 18 U.S.C. § 3582(c)(1)(A), arguing that he was entitled to a sentence reduction due to inadequate medical care for various health conditions and factual disputes surrounding his sentencing calculations.
The Court’s Holding
The court denied the motion, finding that Crookshank failed to satisfy the three-prong test for compassionate release: extraordinary and compelling circumstances, consistency with Sentencing Commission policy statements, and favorability under the 18 U.S.C. § 3553(a) sentencing factors. Regarding his medical care claims, the court held that although Crookshank suffered from various conditions including hypertension, kidney problems, and a ruptured spleen, he had admitted to receiving treatment from qualified doctors. The court emphasized that disagreement with the care and treatment received does not establish that long-term medical care is being denied.
On Crookshank’s factual disputes—specifically his arguments about drug weight calculations, guideline enhancements, and sentencing disparities—the court ruled these claims were not cognizable under § 3582(c). The proper vehicle for challenging the legality or duration of a sentence is a § 2255 motion, not a compassionate release motion. Finally, the court examined the § 3553(a) factors and found them decisively against reduction: the nature and seriousness of the offense (large-scale drug trafficking with firearms), Crookshank’s extensive criminal history (six felony and seven misdemeanor convictions), and the need for deterrence and public protection all weighed toward maintaining the sentence.
Key Takeaways
- Compassionate release under § 3582(c) requires “extraordinary and compelling” circumstances—a high bar that courts interpret narrowly
- A defendant’s disagreement with medical care received, even if inadequate in the defendant’s view, does not establish denial of long-term medical care
- Challenges to sentencing calculations, guideline enhancements, and sentence disparity must be raised via § 2255 motion, not compassionate release motions
- The seriousness of the offense and extent of criminal history are decisive factors weighing against compassionate release, even when a defendant demonstrates rehabilitative effort
Why It Matters
This decision reinforces the stringent requirements for compassionate release in serious drug trafficking cases. While the First Step Act and § 3582(c) opened a pathway for sentence reduction, courts have consistently interpreted “extraordinary and compelling” to exclude the kinds of claims that might be cognizable in direct appeals or § 2255 proceedings. Crookshank’s case illustrates that courts will distinguish between procedural vehicles for challenging sentences, requiring defendants to follow the correct forum for each type of claim.
For practitioners, the ruling clarifies that medical hardship claims must clear a high threshold—mere inadequacy of care, even when chronic conditions go untreated, is insufficient without evidence that the defendant is at risk of death or serious health deterioration. Similarly, disagreements over sentencing calculations belong in collateral review, not compassionate release proceedings. The decision reflects courts’ concern that permitting such challenges under § 3582(c) would effectively allow end-runs around appellate and collateral review procedures.